911494-26-3

Upstream product

• 140-75-0 para-fluorobenzylamine 
• 911639-71-9 tert-butyl [(2E)-2-amino-1-[(benzyloxy)methyl]-2-(hydroxyimino)ethyl]carbamate 
• 911494-24-1 methyl 5-(benzoyloxy)-2-{2-(benzyloxy)-1-[(tert-butoxycarbonyl)amino]ethyl}-6-hydroxypyrimidine-4-carboxylate 
• 911494-53-6 tert-butyl [2-(benzyloxy)-1-cyanoethyl]carbamate 

Downstream Products

• 911490-61-4 C₂₃H₂₃FN₄O₄ 

Relevant academic research and scientific papers

Routes to HIV-integrase inhibitors: efficient synthesis of bicyclic pyrimidones by ring expansion or amination at a benzylic position

Ring expansion of [6,6] bicyclic pyrimidones led, through an aziridinium intermediate, to potent HIV-integrase inhibitors with a [7,6] core. A more flexible and diversity-oriented synthesis of functionalized pyrimidohexahydrodiazepines was then developed;

HIV INTEGRASE INHIBITORS

Compounds of Formula I are inhibitors of FHV integrase and inhibitors of FHV replication (I), wherein m, n, X, Rl, R2, R3, R4, R5, R6 R7; R8 R9 and R10 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HTV and the prophylaxis, treatment , or delay in the onset of AIDS. The compounds are employed against HTV infection and ADDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.